In recent years, mTOR inhibitors have been approved for treatment of multiple cancers, including renal cell carcinoma, neuroendocrine tumors, and advanced breast cancer, and clinical trials are being conducted in other malignancies [165]. This evidence concerns the gene MTOR and hereditary clear cell renal cell carcinoma.